REFERENCES
1. Shi X, Wang X, Yao W, et al. Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Sig Transduct Target Ther. 2024;9:192.
2. Pallares RM, Consolino L, Wang A, et al. Targeting metastasis with nanomedicine. Nat Rev Bioeng. 2025;4:47-66.
3. Yi M, Li T, Niu M, et al. Exploiting innate immunity for cancer immunotherapy. Mol Cancer. 2023;22:187.
4. Hayday A, Dechanet-merville J, Rossjohn J, Silva-santos B. Cancer immunotherapy by γδ T cells. Science. 2024;386:eabq7248.
5. Geng Q, Xu J, Du C, et al. Small molecules targeting immune checkpoint proteins for cancer immunotherapy: a patent and literature review (2020-2024). Expert Opin Ther Pat. 2025;35:409-40.
6. Yang K, Halima A, Chan TA. Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy. Nat Rev Clin Oncol. 2023;20:604-23.
7. Borgers JSW, Heimovaara JH, Cardonick E, et al. Immunotherapy for cancer treatment during pregnancy. Lancet Oncol. 2021;22:e550-61.
8. Heras-murillo I, Adán-barrientos I, Galán M, Wculek SK, Sancho D. Dendritic cells as orchestrators of anticancer immunity and immunotherapy. Nat Rev Clin Oncol. 2024;21:257-77.
9. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of immunotherapy combination strategies in cancer. Cancer Discovery. 2021;11:1368-97.
10. Oliveira G, Wu CJ. Dynamics and specificities of T cells in cancer immunotherapy. Nat Rev Cancer. 2023;23:295-316.
11. Ye F, Dewanjee S, Li Y, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.
12. Yang Z, Liu X, Zhu J, et al. Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer Cell. 2025;43:86-102.e10.
13. Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther. 2023;8:70.
14. Ghorani E, Swanton C, Quezada SA. Cancer cell-intrinsic mechanisms driving acquired immune tolerance. Immunity. 2023;56:2270-95.
15. Huppert LA, Green MD, Kim L, et al. Tissue-specific Tregs in cancer metastasis: opportunities for precision immunotherapy. Cell Mol Immunol. 2021;19:33-45.
16. Wood H, Acharjee A, Pearce H, et al. Breastfeeding promotes early neonatal regulatory T‐cell expansion and immune tolerance of non‐inherited maternal antigens. Allergy. 2021;76:2447-60.
17. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1-10.
18. Ma J, Hua L, Zhu Y, Mao G, Fu C, Qin S. Photo-thermally controllable tumor metabolic modulation to assist T cell activation for boosting immunotherapy. Int J Nanomedicine. 2024;19:11181-94.
19. Sharma P, Zhang X, Ly K, et al. Hyperglycosylation of prosaposin in tumor dendritic cells drives immune escape. Science. 2024;383:190-200.
20. Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42:1825-63.
21. Gao J, Wang W, Pei Q, Lord MS, Yu H. Engineering nanomedicines through boosting immunogenic cell death for improved cancer immunotherapy. Acta Pharmacol Sin. 2020;41:986-94.
22. Li D, Liu S, Ma Y, Liu S, Liu Y, Ding J. Biomaterials that induce immunogenic cell death. Small Methods. 2023;7:2300204.
23. Lynch C, Pitroda SP, Weichselbaum RR. Radiotherapy, immunity, and immune checkpoint inhibitors. Lancet Oncol. 2024;25:e352-62.
24. Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discovery. 2024;23:445-60.
25. Lauss M, Phung B, Borch TH, et al. Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2024;15:3075.
26. Giles JR, Globig A, Kaech SM, Wherry EJ. CD8+ T cells in the cancer-immunity cycle. Immunity. 2023;56:2231-53.
27. Van Elsas MJ, Middelburg J, Labrie C, et al. Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer Cell. 2024;42:1032-1050.e10.
28. Mellman I, Chen DS, Powles T, Turley SJ. The cancer-immunity cycle: indication, genotype, and immunotype. Immunity. 2023;56:2188-205.
29. Xia D, Zhang X, Hao H, et al. Strategies to prolong drug retention in solid tumors by aggregating Endo-CMC nanoparticles. J Control Release. 2023;360:705-17.
30. Luo X, Huang W, Li S, et al. SOX12 facilitates hepatocellular carcinoma progression and metastasis through promoting regulatory T‐cells infiltration and immunosuppression. Adv Sci. 2024;11:2310304.
31. Chen J, Feng W, Sun M, et al. TGF-β1-induced SOX18 elevation promotes hepatocellular carcinoma progression and metastasis through transcriptionally upregulating PD-L1 and CXCL12. Gastroenterology. 2024;167:264-80.
32. Zhao Y, Pei L, Liu B, et al. Macrophage membrane-coated nanomedicine enhances cancer immunotherapy by activating macrophages and T cells. Mol Pharm. 2025;22:2402-12.
33. Chung JB, Brudno JN, Borie D, Kochenderfer JN. Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol. 2024;24:830-45.
34. Pang Z, Lu M, Zhang Y, et al. Neoantigen-targeted TCR-engineered T cell immunotherapy: current advances and challenges. Biomark Res. 2023;11:104.
35. Zhang L, Lin H, Liang J, et al. Programmed death-ligand 1 regulates ameloblastoma growth and recurrence. Int J Oral Sci. 2025;17:29.
36. Fan Z, Wu C, Chen M, et al. The generation of PD-L1 and PD-L2 in cancer cells: from nuclear chromatin reorganization to extracellular presentation. Acta Pharm Sin B. 2022;12:1041-53.
37. Ma K, Wang L, Li W, et al. Turning cold into hot: emerging strategies to fire up the tumor microenvironment. Trends Cancer. 2025;11:117-34.
38. Peng S, Xiao F, Chen M, Gao H. Tumor‐microenvironment‐responsive nanomedicine for enhanced cancer immunotherapy. Adv Sci. 2021;9:2103836.
39. Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.
40. Goswami S, Pauken KE, Wang L, Sharma P. Next-generation combination approaches for immune checkpoint therapy. Nat Immunol. 2024;25:2186-99.
41. Song L, Hao Y, Wang C, et al. Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer. J Control Release. 2022;350:922-32.
42. Fang M, Zheng J, Song Q, et al. Breaking apoptosis‐induced immune silence: ultrasound‐activated nano‐oncolytic therapy reinvigorates antitumor immunity. Adv Mater. 2025;37:2508681.
43. Yuan Y, Zhuoga C, Zeng C, et al. Advances in nanobody-based platforms for precision cancer diagnosis and therapy. Polym Sci Technol. 2025;1:692-715.
44. Karaosmanoglu S, Zhou M, Shi B, Zhang X, Williams GR, Chen X. Carrier-free nanodrugs for safe and effective cancer treatment. J Control Release. 2021;329:805-32.
45. Ma X, Zhang MJ, Wang J, et al. Emerging biomaterials imaging antitumor immune response. Adv Mater. 2022;34:2204034.
46. Yin Y, Chen Z, Yang C, et al. Spatiotemporally controlled Co-treatment of lung cancer and pulmonary immune-related adverse events by inhalable albumin-chaperoned ultrathin MnO2 nanosheets. ACS Nano. 2025;19:19730-43.
47. Fang H, You P, Lin S, et al. Annexin A1 mRNA-loaded liposomes alleviate acute pancreatitis by suppressing STING pathway and promoting efferocytosis in macrophages. Nat Nanotechnol. 2025;20:1514-25.
48. Kim M, Lee JS, Kim W, et al. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release. 2022;348:893-910.
49. Jia W, Wu Y, Xie Y, Yu M, Chen Y. Advanced polymeric nanoparticles for cancer immunotherapy: materials engineering, immunotherapeutic mechanism and clinical translation. Adv Mater. 2025;37:2413603.
50. Meng Q, Ding B, Ma P, Lin J. Inorganic nanobiomaterials boost tumor immunotherapy: strategies and applications. Acc Chem Res. 2025;58:1210-23.
51. Liu J, Ren L, Li S, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021;11:2783-97.
52. Albertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Delivery Rev. 2022;188:114416.
53. Bauman J, Burris H, Clarke J, et al. 798 Safety, tolerability, and immunogenicity of mRNA-4157 in combination with pembrolizumab in subjects with unresectable solid tumors (KEYNOTE-603): an update. J Immunother Cancer. 2020;8:A1-A559.
54. Lopez J, Powles T, Braiteh F, et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:152-64.
55. Falchook GS, Reeves J, Gandhi S, et al. A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother. 2024;73:72.
56. Su Z, Xu D, Hu X, et al. Biodegradable oxygen-evolving metalloantibiotics for spatiotemporal sono-metalloimmunotherapy against orthopaedic biofilm infections. Nat Commun. 2024;15:8058.
57. Zhu Y, Chen P, Hu B, et al. MDSC-targeting gold nanoparticles enhance PD-1 tumor immunotherapy by inhibiting NLRP3 inflammasomes. Biomaterials. 2024;307:122533.
58. Hollingsworth D, Srivastava S, Akter S, et al. Colostrum extracellular vesicles are neuroprotective in models of Parkinson’s disease. Theranostics. 2026;16:4190-223.
59. Wang F, Yin L, Hu Y. Progress of extracellular vesicles-based system for tumor therapy. J Control Release. 2025;381:113570.
60. Zhao L, Gu C, Gan Y, Shao L, Chen H, Zhu H. Exosome-mediated siRNA delivery to suppress postoperative breast cancer metastasis. J Control Release. 2020;318:1-15.
61. Li Y, Liu F, Cai Q, et al. Invasion and metastasis in cancer: molecular insights and therapeutic targets. Sig Transduct Target Ther. 2025;10:57.
62. Zhang J, Liu J, Wang Y, et al. Macrophage hitchhiking for smart nanomedicine: bridging immune navigation and targeted therapy. J Control Release. 2025;386:114155.
63. Luo J, Chen J, Zhou J, et al. Harnessing smart nanomaterials to reprogram neutrophil plasticity in immune modulation. J Nanobiotechnol. 2025;23:666.
64. Zhang X, Cai H, Peng W, et al. Lenvatinib plus transarterial chemoembolization and PD-1 inhibitors as conversion therapies for unresectable intermediate-advanced hepatocellular carcinoma: a phase 2 trial and exploratory biomolecular study. Sig Transduct Target Ther. 2026;11:37.
65. Mo H, Yu Y, Sun X, et al. Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med. 2024;30:2528-39.
66. Wang Y, Dong A, Man J, et al. TREM2 scFv‐engineering escherichia coli displaying modulation of macrophages to boost cancer radio‐immunotherapy. Adv Mater. 2025;37:2417920.
67. Zhang Z, Zhang X, Chen D. Using triple radio-immunotherapy to overcome cancer immunotherapy resistance. Cancer Biol Med. 2023;20:788.
68. Huang J, Theelen WSME, Belcaid Z, et al. Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer. Nat Cancer. 2025;6:1676-92.
69. Gu C, Wang X, Wang K, et al. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer. J Immunother Cancer. 2024;12:e008386.
70. Gu S, Luo Q, Zhang Y, et al. Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial. Nat Cancer. 2025;7:60-79.
71. Hajjar R, Mars RAT, Kashyap PC. Harnessing the microbiome for cancer therapy. Nat Rev Microbiol. ;2026:1268.
72. Porcari S, Ciccarese C, Heidrich V, et al. Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial. Nat Med. 2026;32:1316-24.
73. Sun Y, Yang H, Xu Q, et al. Anti‐PD‐1 nanobody‐armored MSLN CAR‐T Therapy for malignant mesothelioma: preclinical and clinical studies. Adv Sci. ;2025:e08754.
74. Wang Y, Jia J, Wang F, et al. Pre-metastatic niche: formation, characteristics and therapeutic implication. Sig Transduct Target Ther. 2024;9:236.
75. Cambria E, Coughlin MF, Floryan MA, Offeddu GS, Shelton SE, Kamm RD. Linking cell mechanical memory and cancer metastasis. Nat Rev Cancer. 2024;24:216-28.
76. Cooper AJ, Sequist LV, Lin JJ. Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management. Nat Rev Clin Oncol. 2022;19:499-514.
77. Liu H, Zhao H, Sun Y. Tumor microenvironment and cellular senescence: understanding therapeutic resistance and harnessing strategies. Semin Cancer Biol. 2022;86:769-81.
78. Jin Y, Huang Y, Ren H, et al. Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment. Biomaterials. 2024;305:122463.
79. Fan D, Cao Y, Cao M, Wang Y, Cao Y, Gong T. Nanomedicine in cancer therapy. Sig Transduct Target Ther. 2023;8:293.
80. Maksymova L, Pilger YA, Nuhn L, Van Ginderachter JA. Nanobodies targeting the tumor microenvironment and their formulation as nanomedicines. Mol Cancer. 2025;24:65.
81. Liu N, Wang X, Wang Z, et al. Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy. J Hematol Oncol. 2025;18:45.
82. Yu M, Yang W, Yue W, Chen Y. Targeted cancer immunotherapy: nanoformulation engineering and clinical translation. Adv Sci. 2022;9:2204335.
83. Sun S, Yu M, Yu L, et al. Nrf2 silencing amplifies DNA photooxidative damage to activate the STING pathway for synergistic tumor immunotherapy. Biomaterials. 2023;296:122068.
84. Lei L, Dong Z, Xu L, et al. Metal-fluorouracil networks with disruption of mitochondrion enhanced ferroptosis for synergistic immune activation. Theranostics. 2022;12:6207-22.
85. He S, Huang Y, Liu J, et al. A Metformin-based multifunctional nanoplatform as a DNA damage amplifier for maximized radio-immunotherapy to overcome radiotherapy resistance. ACS Nano. 2025;19:14848-64.
86. Meng M, Wu J, Guo X, et al. An injectable photothermal-fusing hydrogel: achieving temperature-controllable mild photothermal therapy to reverse chemotherapy-induced immune tolerance. Nano Lett. 2024;24:13044-53.
87. Zhou F, Gao J, Tang Y, et al. Engineering chameleon prodrug nanovesicles to increase antigen presentation and inhibit PD‐L1 expression for circumventing immune resistance of cancer. Adv Mater. 2021;33:2102668.
88. Dang Y, Hou B, Pan J, et al. In Situ Transformable photothermal targeting chimeras for spatiotemporally controllable protein degradation and combination immunotherapy for cancer. J Am Chem Soc. 2026;148:2388-404.
89. Hu B, Stewart W, Chen Q, et al. Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA. Nat Commun. 2025;16:8120.
90. Kong X, Xie X, Wu J, et al. Combating cancer immunotherapy resistance: a nano‐medicine perspective. Cancer Commun. 2025;45:813-40.
91. Hao X, Shen Y, Liu J, et al. Solid tumour-induced systemic immunosuppression involves dichotomous myeloid-B cell interactions. Nat Cell Biol. 2024;26:1971-83.
92. Lan J, Li H, Xue J, Duan Y, Sun J, Niu M. The immune microenvironment in liver cancer: from analysis to targeting. Adv Sci. 2025;12:e18487.
93. Wu B, Wang Z, Liu J, et al. Dual rectification of metabolism abnormality in pancreatic cancer by a programmed nanomedicine. Nat Commun. 2024;15:10526.
94. Pu T, Sun J, Ren G, Li H. Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications. Sig Transduct Target Ther. 2025;10:176.
95. Amit M, Eichwald T, Roger A, et al. Neuro-immune cross-talk in cancer. Nat Rev Cancer. 2025;25:573-89.
96. Zhang Z, Chen P, Zheng Y, et al. Oxidation-activated nanotherapy boosts tumor immunity and disrupts tumor-nerve crosstalk to combat bone metastases and cancer pain. Sci. Adv. 2026;12:eady1292.
97. Masoumi E, Tahaghoghi-hajghorbani S, Jafarzadeh L, Sanaei M, Pourbagheri-sigaroodi A, Bashash D. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle. J Control Release. 2021;340:168-87.
98. Hunter TL, Bao Y, Zhang Y, et al. In vivo CAR T cell generation to treat cancer and autoimmune disease. Science. 2025;388:1311-7.
99. Tao Z, Kuai X, Wang G, et al. Combination of chemotherapy and immune checkpoint therapy by the immunoconjugates-based nanocomplexes synergistically improves therapeutic efficacy in SCLC. Drug Delivery. 2022;29:1571-81.
100. Chen F, Zhang H, Li S, et al. Polypeptide sono-adjuvant for ultrasound-activatable regulation of innate immunity and cancer vaccination therapy. Nat Commun. 2025;17:272.
101. Tian W, Xie Y, Su H, Zheng C, Li M. Explainable artificial intelligence-driven salivary exosome spectroscopic profiling for clinical diagnosis and metastasis detection of oral cancer. Nano Lett. 2026;26:2279-88.
102. Liu Y, Li Y, Gong W, et al. An immune nanoenhancer revitalizes chemotherapeutics to tailor tumor‐derived dsDNA for anticancer immunoengineering. Adv Mater. 2025;38:e16524.
103. Pan Y, Cheng J, Zhu Y, Zhang J, Fan W, Chen X. Immunological nanomaterials to combat cancer metastasis. Chem Soc Rev. 2024;53:6399-444.
104. Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell. 2025;43:665-79.
